Research and Markets: Erectile Dysfunction - Pipeline Review, H1 2013

<0> Research and Markets: Erectile Dysfunction - Pipeline Review, H1 2013 </0>

<0> Research and MarketsLaura Wood, Senior Manager.U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716Sector: , </0>

() has announced the addition of the report to their offering.

Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction.

Scope

- A snapshot of the global therapeutic scenario for Erectile Dysfunction.

- A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Erectile Dysfunction pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Companies Mentioned

- Acorda Therapeutics, Inc.

- Bayer AG

- Chong Kun Dang Pharmaceutical

- Dong-A Pharmaceutical Co., Ltd.

- Futura Medical plc.

- Global Health Ventures Inc.

- IntelGenx Technologies Corp.

- Medisyn Technologies, Inc.

- NexMed, Inc.

- Palatin Technologies, Inc.

- Quatrx Pharmaceutical Company

- Rexahn Pharmaceuticals, Inc.

- Sanofi-Aventis

- VIVUS, Inc.

- Vectura Group plc

- Yuhan Corporation

For more information visit

On-Demand Webinar

Leveraging A Medical Record-Enriched Patient Dataset for COVID-19 Research

You are invited to join a webinar that will explore the ways researchers can leverage this enriched dataset for important COVID-19 research. Sign up today for this informative webinar to learn how you can leverage one of the only medical record reviews solely using real-world data from hospitalized COVID-19 patients.

Suggested Articles

Life sciences companies have pivoted quickly during COVID-19 - Syneos Health® is supporting more than 80 active COVID-19 projects, including vaccines.

New York's Covaxx has signed on with three South American nations to provide 140 million doses of its early-stage COVID-19 vaccine.

To get the COVID-19 vaccine out quickly, Pfizer has been running rehearsals at distribution sites, creating "growing confidence," U.S. officials said.